Ph-Positive Acute Lymphoblastic Leukemia: Dasatinib/Blinatumomab Effective in Phase 2

Positive survival outcomes were observed in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when treated with dasatinib followed by blinatumomab in in a phase 2 study now published in the New England Journal of Medicine. For the trial, adults with newly diagnosed Ph-positive ALL were given a seven-day prephase treatment with a glucocorticoid prior to the first administration of dasatinib in a 140 mg dose. Glucocorticoids were continued for 24 more days...
Continue reading

Trunk and Extremity Melanoma Debate: Similar Outcomes for Mohs Micrographic Surgery Versus Wide Local Excision

Survival outcomes did not change significantly for patients with melanoma of the trunk or extremity when treated with Mohs micrographic surgery (MMS) compared with wide local excision, according to the results of a retrospective cohort study published recently in JAMA Dermatology. The retrospective cohort study was designed because previous studies indicated differences in overall survival outcomes for patients with head and neck cancers. However, this study indicates that those results do not a...
Continue reading

Pembrolizumab Approved for Classical Hodgkin Lymphoma

PembrolizumabThe FDA has now expanded the approved indications for pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme) to include both adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy. The approval was based on efficacy data from the open-label phase 3 KEYNOTE-204 trial (NCT02684292), for which 304 adult patients with cHL previously treated with at least one multiagen...
Continue reading

In HER2-Negative Metastatic Breast Cancer, Adding CDK4/6 Inhibitor to Endocrine Therapy Helps Survival

 Endocrine therapy plus cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors improved overall survival, progression-free survival, and objective response rate for patients with hormone receptor–positive, HER2-negative metastatic breast cancer, according to results of a meta-analysis published recently in JAMA Oncology. The finding supports continued use of endocrine therapy plus CDK4/6 inhibitor combinations in clinical trials. The investigators, led by first author Jinming Li, BD, a pr...
Continue reading

In Acute Myeloid Leukemia, Measurable Residual Disease Correlates With Survival

Measurable residual disease correlates with disease-free survival and overall survival data for patients with acute myeloid leukemia (AML), according to results of a meta-analysis published today in JAMA Oncology. This finding supports the continued use of measurable residual disease as a surrogate end point in clinical trials. The investigators, led by first author Nicholas Short, MD, Assistant Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houst...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.